About Axsome Therapeutics
Axsome Therapeutics is a company based in New York (United States) founded in 2012.. Axsome Therapeutics has raised $8.7 million across 6 funding rounds from investors including SVB Securities. The company has 683 employees as of December 31, 2024. Axsome Therapeutics has completed 2 acquisitions, including Baergic Bio and SUNOSI. Axsome Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter New York, United States
- Employees 683 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Axsome Therapeutics, Inc.
-
Annual Revenue
$385.69 M42.53as on Dec 31, 2024
-
Net Profit
$-287.22 M-20.05as on Dec 31, 2024
-
EBITDA
$-244.48 M-38.85as on Dec 31, 2024
-
Total Equity Funding
$8.7 M (USD)
in 6 rounds
-
Latest Funding Round
$26 M (USD), Post-IPO
Jan 07, 2019
- Investors
-
Employee Count
683
as on Dec 31, 2024
-
Investments & Acquisitions
Baergic Bio
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Axsome Therapeutics
Axsome Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AXSM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Specialty Team
52 people
Leadership Team
51 people
Software Development Team
23 people
Sales and Marketing
21 people
Finance and Accounting
8 people
Senior Team
6 people
Data Analysis and Operations Team
3 people
Human Resources and Administration
3 people
Unlock access to complete
Funding Insights of Axsome Therapeutics
Axsome Therapeutics has successfully raised a total of $8.7M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $26 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $26.0M
-
First Round
First Round
(04 Mar 2013)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2019 | Amount | Post-IPO - Axsome Therapeutics | Valuation |
investors |
|
| May, 2015 | Amount | Series A - Axsome Therapeutics | Valuation |
investors |
|
| Jan, 2015 | Amount | Debt – Conventional - Axsome Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Axsome Therapeutics
Axsome Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include SVB Securities. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
M&A advisory services are provided for healthcare companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Axsome Therapeutics
Axsome Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Baergic Bio and SUNOSI. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel therapeutics for CNS disorders are developed and commercialized.
|
2019 | ||||
|
Official website of prescribed drug for the treatment of excessive daytime sleepiness
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Axsome Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Axsome Therapeutics Comparisons
Competitors of Axsome Therapeutics
Axsome Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| domain | founded_year | HQ Location |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Axsome Therapeutics
Frequently Asked Questions about Axsome Therapeutics
When was Axsome Therapeutics founded?
Axsome Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is Axsome Therapeutics located?
Axsome Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Axsome Therapeutics a funded company?
Axsome Therapeutics is a funded company, having raised a total of $8.7M across 6 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1.32M, raised on Mar 04, 2013.
How many employees does Axsome Therapeutics have?
As of Dec 31, 2024, the latest employee count at Axsome Therapeutics is 683.
What is the annual revenue of Axsome Therapeutics?
Annual revenue of Axsome Therapeutics is $385.69M as on Dec 31, 2024.
What does Axsome Therapeutics do?
Developer of therapeutics for the management of CNS disorders. The companys pipeline includes two late-stage product candidates, AXS-05 (bupropion and dextromethorphan) and AXS-02 (disodium zoledronate tetrahydrate) for multiple indications including treatment-resistant depression, agitation in Alzheimers disease, complex regional pain syndrome (CRPS), Knee Osteo Arthritis related bone marrow lesions (BMLs) and chronic low back pain.
Who are the top competitors of Axsome Therapeutics?
Axsome Therapeutics's top competitors include Alector, Entrada Therapeutics and Annexon.
Is Axsome Therapeutics publicly traded?
Yes, Axsome Therapeutics is publicly traded on NASDAQ under the ticker symbol AXSM.
How many acquisitions has Axsome Therapeutics made?
Axsome Therapeutics has made 2 acquisitions, including Baergic Bio, and SUNOSI.
Who are Axsome Therapeutics's investors?
Axsome Therapeutics has 1 investor. Key investors include SVB Securities.
What is Axsome Therapeutics's ticker symbol?
The ticker symbol of Axsome Therapeutics is AXSM on NASDAQ.